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Aim To investigate the prognostic role of C-reactive protein 
(CRP) and renal function for the occurrence of major ad-
verse cardiovascular events (MACE) in patients with symp-
tomatic peripheral artery disease (PAD) and preserved left 
ventricular ejection fraction (LVEF).
Methods The occurrence of MACE, defined as compos-
ite endpoint of acute myocardial infarction, urgent coro-
nary revascularization, stroke, and death was assessed in 
319 consecutive PAD patients admitted to the University 
Hospital between January 2010 and January 2014 (66.5% 
men, mean [±standard deviation] age 70 ± 10 years, mean 
ankle brachial index 0.58 ± 0.14) with normal LVEF (>50%). 
Multivariate Cox regression analysis adjusted for age, sex, 
traditional cardiovascular risk factors, anemia, polyvascular 
disease, critical limb ischemia (CLI), statin treatment, CRP 
(>5 mg/L), and impaired renal function (estimated glom-
erular filtration rate <60 mL/min) was applied to assess the 
independent predictors of MACE.
Results During median follow-up period of 24 months (in-
terquartile range, 16-34 months), 77 patients (24%) experi-
enced MACE. Compared to patients without MACE, these 
patients were older, more likely to have CLI, polyvascular 
disease, anemia, elevated CRP, and impaired renal function. 
In multivariate regression analysis, age (HR 1.04, 95% CI 
1.01-1.07), polyvascular disease (HR 1.95, 95% CI 1.23-3.09), 
elevated CRP (HR 1.89, 95% CI 1.18-3.02), and impaired re-
nal function (HR 1.68, 95% C 1.01-2.78) remained indepen-
dent predictors of MACE. Patients with both impaired re-
nal function and high CRP values on admission were 3.59 
times more likely to experience MACE than patients with 
normal CRP and preserved renal function.
Conclusion Elevated admission CRP and renal impair-
ment are independent predictors of MACE in symptomatic 
PAD patients with preserved LVEF.
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C-reactive protein (CRP) is a simple marker, widely commer-
cially available and regularly used in daily clinical practice. 
While CRP is well studied in acute coronary syndromes, its 
predictive role in symptomatic peripheral artery disease 
(PAD) is less clear (1). Conflicting data were published re-
garding the prognostic significance of admission CRP in 
patients with PAD (2-5). Its prognostic relevance may be 
affected by disease severity, duration of follow-up period, 
and inclusion of traditional risk factors.
Patients with chronic kidney disease have an increased risk 
of developing PAD (6,7). Data regarding the prognostic 
implication of impaired renal function in PAD patients are 
scarce. Despite interrelated pathophysiology of inflamma-
tion and renal function, their prognostic role has not been 
clarified in the clinical setting of symptomatic PAD. Left 
ventricular systolic dysfunction is associated with worse 
outcome and its prevalence is significantly higher in pa-
tients with peripheral vascular disease than in general pop-
ulation (8,9). However, this parameter was not included in 
prior outcome studies. Therefore, the aim of our research 
was to investigate the prognostic impact of CRP and im-
paired renal function for MACE in a cohort of consecutive 
patients with symptomatic PAD and preserved left ventric-
ular systolic function.
PATienTs And MeThods
Between January 2010 and January 2014 we studied 319 
consecutive patients with symptomatic PAD (Fontaine 
stages IIB – 58%, III – 24%, and IV – 18%), admitted to the 
University Hospital. 16 patients were not included due to 
malignancy (12 patients) and concomitant autoimmune 
disorders (4 patients). The diagnosis of PAD was estab-
lished by clinical examination, ankle brachial index mea-
surement, duplex sonography and/or computed tomogra-
phy or magnetic resonance, angiography, and confirmed 
with peripheral angiography using the criteria of the Euro-
pean Society of Cardiology and American College of Cardi-
ology Foundation (10,11).
Baseline clinical characteristics and demographic data 
were recorded during the hospital stay and included gen-
eral information (age, sex, weight, and height), data about 
cardiovascular risk factors, biochemical and hematological 
laboratory data, and data on comorbidities and medica-
tions. The diagnosis of hypertension was made in accor-
dance with the European Society of Cardiology/Euro-
pean Society of Hypertension 2013 guidelines (12). 
Left ventricular ejection fraction (LVEF) was assessed 
using transthoracic echocardiography (Simpson’s meth-
od), and only patients with preserved LV systolic function 
(LVEF>50%) were included in the study. Cardiovascular dis-
ease (CVD), in addition to confirmed PAD, was defined as 
history of angina, myocardial infarction, coronary revascu-
larization (percutaneous coronary intervention [PCI] or cor-
onary artery bypass grafting [CABG]), history of stroke, tran-
sient ischemic attack, or carotid revascularization.
High sensitivity CRP was determined on admission by im-
munoturbidimetric method (Olympus, Dublin, Ireland). 
Estimated glomerular filtration rate (eGFR) was calculated 
using the Modification of Diet in Renal Disease formula. 
Baseline anemia was defined according to World Health Or-
ganization criteria (hemoglobin level <13 g/dL for men and 
<12 g/dL for women) (13).The investigation was performed 
in accordance with the Declaration of Helsinki and was ap-
proved by the University Hospital Ethics Committee.
Patients were followed up for the occurrence of the first 
major adverse cardiovascular event (MACE), defined as 
composite endpoint of acute myocardial infarction, ur-
gent revascularization (PCI or CABG), stroke, and death. 
Peripheral vascular events (revascularization procedures 
or amputations) during follow-up were not considered as 
a study endpoint. The median follow-up was 24 months 
(interquartile range, 16-34 months). Patients were followed 
up in the outpatient clinic at 3, 6, and 12 months after 
discharge and then annually. Furthermore, periodic tele-
phone interviews were performed to determine the oc-
currence of events. Mortality was documented by death 
certificates or by reviewing the hospital records. Outcome 
was assessed by independent observers, who were blind-
ed to patients’ laboratory and clinical data.
Continuous normally distributed variables are expressed as 
mean (±standard deviation) and not-normally distributed 
variables as medians (interquartile range). Differences be-
tween the groups were analyzed with t test and Mann-Whit-
ney test for continuous variables and with χ2-square test for 
categorical variables. Normality of distribution was tested 
with Kolmogorov-Smirnov test. The ability of CRP and eGFR 
to predict MACE was tested by receiver-operating charac-
teristic (ROC) analyses. Kaplan-Meier analysis with log-rank 
test was performed and comparison was based on optimal 
cut-off points of CRP (dichotomized to > or<5 mg/L) and 
eGFR (dichotomized to > or<60 mL/min) based on ROC 
analyses and previously published data (2). Cox proportion-
al-hazards regression analysis was performed to determine 
the independent predictors of MACE and results were ex-
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pressed as hazard ratios (HR) and 95% confidence inter-
vals (CI). Covariate selection included known correlates of 
poor cardiovascular outcome and those that were found to 
be significant in the univariate analysis (univariate P value 
<0.100), namely age, sex, traditional cardiovascular risk fac-
tors, anemia, history of cardiovascular disease, critical limb 
ischemia, and statin treatment. CRP and eGFR were en-
tered in multivariate analysis as binary variables. The value 
of P < 0.050 was considered statistically significant. Statisti-
cal analysis was performed using MedCalc® Version 11.3.1.0 
(MedCalc, Ostend, Belgium).
ResulTs
The baseline characteristics of the 319 symptomatic PAD 
patients are summarized in Table 1. During median fol-
low-up period of 24 months (interquartile range, 16-34 
months), 77 patients (24%) had a MACE, with 20 myocar-
dial infarctions, 8 percutaneous coronary interventions/
CABG procedures, 11 strokes, and 38 deaths. In the uni-
variable analysis older age (P < 0.001), critical limb ischemia 
(P = 0.012), anemia (P = 0.018), history of cardiovascular 
disease (P = 0.002), decreased eGFR (P < 0.001), and high-
er CRP values (P = 0.009) were significantly associated with 
MACE (Table 2).
CRP (P = 0.008) and eGFR (P < 0.001) predicted freedom 
from MACE (Figure 1A and 1B). In logistic regression anal-
ysis, critical limb ischemia (odds ratio [OR] 4.59, 95% CI 
2.76-7.63; P < 0.001), anemia (OR 2.15, 95% CI 1.14-4.05; 
P = 0.017), and hypertension (OR 3.44, 95% CI 1.48-7.97; 
P = 0.004) were significantly associated with elevated CRP 
values, while age (OR 1.09, 95% CI 1.07-1.13; P < 0.001) was 
associated with impaired renal function. Baseline hemo-
globin levels negatively correlated (Spearman correlation 
test) with CRP values (ρ = -0.232; P < 0.001), and positively 
with eGFR (ρ = 0.328; P < 0.001).
In multivariable Cox regression analysis, age, polyvascular 
disease, elevated CRP, and impaired renal function inde-
TABle 2. univariate and multivariate Cox proportional-hazards regression analysis for major adverse cardiovascular events*
univariate Multivariate
Variable hR (95% Ci) P hR (95% Ci) P
Age 1.048 (1.022-1.075) <0.001 1.036 (1.009-1.065) 0.010
Female sex 1.254 (0.795-1.979) 0.333 -
Hypertension 2.905 (1.067-7.910) 0.038 -
Diabetes mellitus 1.084 (0.690-1.703) 0.727 -
Smoking 1.124 (0.715-1.765) 0.615 -
Dyslipidemia 1.077 (0.633-1.831) 0.786 -
Critical limb ischemia 1.798 (1.138-2.840) 0.012 -
Coronary artery disease 1.499 (0.947-2.375) 0.085 -
Polyvascular disease 2.045 (1.306-3.201) 0.002 1.945 (1.225-3.088) 0.005
hsCRP (>5 mg/L) 1.861 (1.165-2.972) 0.009 1.887 (1.179-3.022) 0.008
eGFR (<60 mL/min) 2.464 (1.551-3.912) <0.001 1.677 (1.012-2.778) 0.045
Anemia 1.775 (1.103-2.855) 0.018 -
Statin therapy 1.001 (0.635-1.578) 0.996 -
*hR – hazard ratio; Ci – confidence interval; hsCRP – high sensitivity C-reactive protein; eGFR – estimated glomerular filtration rate.
TABle 1. Baseline characteristics of 319 patients with symp-
tomatic peripheral artery disease
Characteristic
Age (years)*  71 (63-78)
Male sex, n (%) 212 (66.5)
Ankle brachial index†   0.58 ± 0.14
Systolic blood pressure (mmHg)* 140 (130-154)
Diastolic blood pressure (mmHg)*  80 (80-90)
Heart rate (beat/min)*  75 (67-80)
Body mass index (kg/m2)*  27 (25-30)
Hypertension, n (%) 277 (87)
Diabetes mellitus, n (%) 172 (54)
Smoking, n (%) 173 (54)
Dyslipidemia, n (%) 242 (76)
Polyvascular disease, n (%) 132 (41)
Critical limb ischemia, n (%) 134 (42)
Anemia, n (%)  67 (21)
High sensitivity C-reactive protein (mg/L)*   4.5 (2.2-10.0)
Estimated glomerular filtration rate (mL/min)†  63.4 ± 18.3
Left ventricular ejection fraction (%)†  57.0 ± 5.5
Statin therapy, n (%) 194 (61)
Antiplatelet therapy, n (%) 299 (94)
*Median (interquartile range).
†Mean ± standard deviation.
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pendently predicted MACE (Table 2). Patients having both 
impaired renal function and high CRP values at baseline 
were 3.59 times (95% CI = 1.89-6.83; P < 0.001) more likely 
to experience MACE than patients with normal CRP and 
preserved renal function (Figure 1C).
disCussion
This study found that the baseline CRP, renal function, age 
and polyvascular disease were independent predictors of 
MACE. Additionally, patients with both renal impairment 
and elevated CRP values at baseline had the highest risk 
for MACE.
PAD is one of the most frequent manifestations of athero-
sclerosis and is associated with a very high risk of ischemic 
events, ie, myocardial infarction, stroke, and death (14). 
Therefore, besides early diagnosis and treatment it is im-
portant to timely assess the risk for cardiovascular events.
While CRP is well studied in acute coronary and acute aor-
tic syndromes (1,15,16), its prognostic role in symptomatic 
PAD is still controversial (5). In line with our results, Owens 
et al showed independent prognostic value of CRP (>5 
mg/L) for all-cause mortality in PAD patients undergo-
ing bypass surgery (2). Schlager et al showed that base-
line CRP (>8.8 mg/L) predicted MACE in patients who un-
derwent angioplasty due to symptomatic PAD (3). On the 
other hand, Breveti et al showed that CRP did not predict 
myocardial infarction or stroke (4). Of note, left ventricu-
lar systolic function, although associated with poor out-
come was not investigated in these studies. We investi-
gated patients with preserved ejection fraction who 
received conservative or endovascular treatment together 
with patients who underwent lower extremity bypass op-
eration and evaluated a broad spectrum of adverse cardio-
vascular outcomes which makes our sample similar to the 
population treated in the daily clinical practice.
Chronic kidney disease (CKD) is associated with adverse 
outcomes in patients with cardiovascular disease, namely 
acute coronary syndromes, after percutaneous coronary 
intervention and coronary artery bypass surgery (17,18). 
However, little attention has been paid to the prognostic 
role of renal function in symptomatic PAD patients, keep-
ing in mind that CKD and PAD share some common risk 
factors (6). Renal impairment was found to predict all-
cause mortality in patients with symptomatic PAD (19). We 
believe this is the first report that showed the indepen-
dent prognostic role (defined as the occurrence of MACE) 
of impaired renal function in patients with severe PAD, re-
gardless of conventional risk factors, disease severity, and 
inflammation.
Patients with polyvascular disease have an increased risk of 
death (20). The results from the REduction of Atherothrom-
bosis for Continued Health registry showed that patients 
with atherosclerotic disease affecting two or more vascular 
beds had significantly worse prognosis than patients with 
single arterial bed disease (21). In our study, patients with 
polyvascular disease were two times more likely to suffer 
adverse outcomes than those with isolated peripheral ar-
tery disease.
A limitation of our study is that we did not routinely check 
parathyroid hormone levels in PAD patients, which might 
FiGuRe 1. Cumulative major adverse cardiovascular events (MACe) free survival according to: (A) baseline high sensitivity C-reactive 
protein (hsCRP), (B) estimated glomerular filtration rate (eGFR), and (C) combined effect of baseline hsCRP and eGFR in 319 patients 
with symptomatic peripheral artery disease.
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be a contributing factor to the worsening of atherosclerot-
ic process. In conclusion, our data show that elevated ad-
mission CRP values and renal impairment are independent 
prognostic factors of adverse clinical outcome in patients 
with symptomatic PAD and preserved LVEF. The coexis-
tence of impaired renal function and inflammation sub-
stantially increase the risk of future ischemic events.
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